Walpar Nutritions share price
NSE: WALPARPharmaceuticals & Biotechnology
Walpar Nutritions Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2021 · Issue price ₹55
Last close ₹25.00down ₹1.10 (4.21%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹26.10.
28 Oct: open ₹25.00, high ₹25.00, low ₹25.00
52-week range of traded prices to 28 Oct 2026
₹21.25Low, 12 Jun 2026₹50.60High, 22 Dec 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹23 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 9.49
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.24
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.76
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,000100.0% delivered
Results
Consolidated; ₹ crore.Walpar Nutritions half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +9.8%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −42.7%
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹42 Crup 15.91%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.18 Crdown 8.91%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 2.8%
Revenue by half year
Peak revenue ₹42 Cr, half year to Mar 2026; lowest ₹17 Cr, half year to Sep 2022
Net profit by half year, a loss in red
- Net profit
- Loss
A loss in 1 of the 8 half years shown
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.5 | 18.6 | 31.1 | 31.4 | 32.5 | 39.2 | 36.5 | 42.3 |
| Net profit | −0.4 | 1.0 | 0.4 | 1.2 | 2.6 | 1.7 | 1.3 | 1.2 |
| Net margin | −2.3% | 5.2% | 1.3% | 3.8% | 7.9% | 4.4% | 3.5% | 2.8% |
Consolidated. The last eight half years. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹79 Crup 9.79%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2.47 Crdown 24.37%
- Net margin
- 3.1%
Revenue by year
Peak revenue ₹79 Cr, year to Mar 2026; lowest ₹35 Cr, year to Mar 2023
Net profit by year, a loss in red
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 35.1 | 62.5 | 71.8 | 78.8 |
| Net profit | 0.6 | 1.6 | 3.3 | 2.5 |
| Net margin | 1.7% | 2.5% | 4.6% | 3.1% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturing and Trading of Pharmaceutical, Nutraceutical, Herbal and Ayurvedic Commodities, which carries all its revenue.
Walpar Nutritions competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Walpar Nutritions in market cap. Walpar Nutritions' own figures are from its last trade, on 28 Oct 2026. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Gujarat Terce LaboratoriesGUJTERC | 32 | 15.35 | 3.29 | −7.2% | – | 25.8% | 25.8% | 0.00% |
 Medi CapsMEDICAPQ | 31 | – | 0.28 | −42.9% | – | −1.5% | −8.7% | 0.00% |
 Goldline PharmaceuticalGLPL | 30 | 7.28 | 2.10 | – | – | 28.9% | – | 0.00% |
 Bacil PharmaBACPHAR | 27 | – | 1.07 | – | – | – | −0.7% | 0.00% |
 Lasa SupergenericsLASA | 23 | – | 0.47 | −95.2% | – | −24.8% | −24.8% | 0.00% |
 Welcure Drugs & PharmaceuticalsWELCURE | 22 | – | – | – | – | – | – | 0.00% |
 Ishita Drugs & IndustriesISHITADR | 22 | 31.03 | 1.89 | −28.6% | −31.0% | 6.3% | 5.3% | 0.00% |
 Zenith Health CareZENITHHE | 20 | 474.54 | 2.62 | −5.4% | – | 0.6% | −4.1% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Walpar Nutritions announcements
Oct 2026
Sep 2026
Aug 2026
29 Aug
Walpar Nutritions share price by year
Each calendar year to 2025.Walpar Nutritions share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 47.85 | −5.2% | 52.50 | 38.85 |
| 2024 | 50.50 | +22.2% | 73.33 | 39.00 |
| 2023 | 41.33 | +31.3% | 50.83 | 25.00 |
| 2022 | 31.48 | +114.1% | 39.75 | 13.13 |
| 2021 | 14.70 | – | 28.50 | 13.80 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 13 Jul 2021.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 26.10 | 26.10 | 26.10 | 26.10 | 26.10 | 2,000 | 100.0% |
| 13 Oct 2026 | 26.10 | 26.10 | 26.10 | 26.10 | 26.10 | 2,000 | 100.0% |
| 5 Oct 2026 | 28.45 | 28.45 | 26.10 | 26.10 | 26.64 | 14,000 | 57.1% |
| 1 Oct 2026 | 29.00 | 29.00 | 27.40 | 27.40 | 28.20 | 4,000 | 100.0% |
| 30 Sep 2026 | 27.40 | 28.45 | 27.40 | 28.45 | 28.04 | 8,000 | 100.0% |
| 29 Sep 2026 | 24.95 | 27.40 | 24.95 | 27.40 | 26.18 | 4,000 | 100.0% |
| 28 Sep 2026 | 28.75 | 28.80 | 26.10 | 26.25 | 28.01 | 20,000 | 70.0% |
| 25 Sep 2026 | 27.95 | 27.95 | 25.80 | 27.45 | 27.35 | 16,000 | 50.0% |
| 24 Sep 2026 | 26.65 | 26.65 | 26.65 | 26.65 | 26.65 | 2,000 | 100.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 14 Aug 2024 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- WALPAR
- ISIN
- INE0G2G01015
- Industry
- Pharmaceuticals & Biotechnology